CN Patent

CN106188192B — 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途

Assigned to Zhejiang Yangli Pharmaceutical Technology Co ltd · Expires 2019-09-10 · 7y expired

What this patent protects

本发明涉及含有非天然D构型氨基酸酯的新型核苷磷酸/膦酸酯前药及其制备方法和用途。所述含有取代苄基的新型核苷磷酸/膦酸酯前药为式(I)或式(II)所示的化合物或其异构体或可药用盐，它可用作各种核苷类似物，例如非环核苷、碳环核苷、呋喃环核苷等的前体药物，强化核苷类化合物的生物活性，从而应用于病毒感染及癌症的治疗。

USPTO Abstract

本发明涉及含有非天然D构型氨基酸酯的新型核苷磷酸/膦酸酯前药及其制备方法和用途。所述含有取代苄基的新型核苷磷酸/膦酸酯前药为式(I)或式(II)所示的化合物或其异构体或可药用盐，它可用作各种核苷类似物，例如非环核苷、碳环核苷、呋喃环核苷等的前体药物，强化核苷类化合物的生物活性，从而应用于病毒感染及癌症的治疗。

Drugs covered by this patent

Patent Metadata

Patent number: CN106188192B
Jurisdiction: CN
Classification: —
Expires: 2019-09-10
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang Yangli Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.